|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drugs |
Neurology Department, Northwestern Memorial Hospital, Chicago, IL 60611 (J.J.R.); Medical College of Wisconsin, Milwaukee, WI 53226 (M.G.M), Memorial Sloan-Kettering Cancer Center, New York, NY 10021 (M.K., L.E.A); USA
2 Address correspondence to Jeffrey J. Raizer, Davee Department of Neurology, Abbott Hall, 710 North Lake Shore Drive, Room 1123, Chicago, IL 60611, USA (j-raizer{at}northwestern.edu).
Abstract
We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents. Patients with malignant gliomas who had undergone radiation therapy were eligible. Patients were treated with TMZ for 28 days, followed by a 28-day rest (1 cycle). The TMZ was started at 50 mg/m2 and increased in 10-mg/m2 increments; a fixed dose of BCNU (150 mg/m2) was given within 72 h of starting TMZ. A standard phase 1 dose-escalation scheme was used with 3 patients per cohort. Fourteen glioblastoma patients and 10 anaplastic astrocytoma patients were treated. The dose-limiting toxicity was myelosuppression at 90 mg/m2 of TMZ. The total number of cycles given was 73 (median number was 2). Six patients (25%) required a dose reduction in BCNU, and six were removed from study for hematologic toxicity after cycle 1; three patients overlapped. The median time to progression and overall survival were, respectively, 82 and 132 weeks for anaplastic astrocytomas and 14 and 69 weeks for glioblastomas. We conclude that the combination of BCNU and the extended dosing schedule of TMZ is feasible and that the maximal tolerated dose of a 28-day course of TMZ is 80 mg/m2 when combined with a fixed dose of BCNU at 150 mg/m2. This is the recommended dose for phase 2, but myelosuppression after cycle 1 suggests that long-term treatment may be difficult.
References
Beith, J., Cook, R., Robinson, B., Levi, J., Bell, D., and Wheeler, H. (1997) Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high-grade gliomas. Proc. Am. Soc. Clin. Oncol. 16, 386a (abstract).
Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J.,
Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K.,
Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D.
(1996) Retrospective study of the correlation between the DNA
repair protein alkyltransferase and survival of brain tumor patients treated
with carmustine. Cancer Res.
56,783
-788.
Brandes, A.A., Turazzi, S., Basso, U., Pasetto, L.M., Guglielmi,
B., Volpin, L., Iuzzolino, P., Amista, P., Pinna, G., Scienza, R., and Ermani,
M. (2002) A multidrug combination designed for reversing
resistance to BCNU in glioblastoma multiforme.
Neurology 58,1759
-1764.
Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall,
B., O'Reilly, M.S., and Folkman, J. (2000) Antiangiogenic
scheduling of chemotherapy improves efficacy against experimental
drug-resistant cancer. Cancer Res.
60,1878
-1886.
Chang, S.M., Yung, W.K.A., Kuhn, J., Schiff, D., Fine, H., Mehta, M., Robins, I., Junck, L., Hess, K., and Prados, M. (2003) Phase II study of neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma. Proc. Am. Soc. Clin. Oncol. 22, 103 (abstract).
Chinot, O.L., Honore, S., Dufour, H., Barrie, M.,
Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.M., and Grisoli,
F. (2001) Safety and efficacy of temozolomide in patients with
recurrent anaplastic oligodendrogliomas after standard radiotherapy and
chemotherapy. J. Clin. Oncol.
19,2449
-2455.
D'Incalci, M., Taverna, P., Erba, E., Filippeschi, S., Potenza, D., Mariani, L., Citti, L., and Catapano, C.V. (1991) O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res. 11,115 -121.[Web of Science][Medline]
de Bono, J., Denis, L., Patnaik, A., Hammond, L., Geyer, C., Gerson, S., Cutler, D., Reyderman, L., Rowinsky, E., and Tolcher, A. (2001) Extended temozolomide (TMZ) dosing schedules permit the administration of higher TMZ dose intensities and inhibit the DNA repair enzyme O6-alkylguanine DNA alkyltransferase (AGAT). Eur. J. Cancer 37,S31 -S32 (abstract).
Fine, H.A., Dear, K.B.G., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71,2585 -2597.[CrossRef][Web of Science][Medline]
Folkman, J. (2003) Angiogenesis and apoptosis. Semin. Cancer Biol. 13,159 -167.[CrossRef][Web of Science][Medline]
Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H.,
Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F.,
Seman, A.J., Cokgor, I., Rich, J., Stewart, E., Colvin, O.M., Provenzale,
J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.
(1998) DNA mismatch repair and O6-alkylguanine-DNA
alkyltransferase analysis and response to Temodal in newly diagnosed malignant
glioma. J. Clin. Oncol.
16,3851
-3857.
Friedman, H.S., Kerby, T., and Calvert, H. (2000a)
Temozolomide and treatment of malignant glioma. Clin. Cancer
Res. 6,2585
-2597.
Friedman, H.S., Pluda, J., Quinn, J.A., Ewesuedo, R.B., Long, L.,
Friedman, A.H., Cokgor, I., Colvin, O.M., Haglund, M.M., Ashley, D.M., Rich,
J.N., Sampson, J., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale,
J.M., Stewart, E.S., Tourt-Uhlig, S., Garcia-Turner, A.M., Herndon, J.E., 2nd,
Bigner, D.D., and Dolan, M.E. (2000b) Phase I trial of carmustine
plus O6-benzylguanine for patients with recurrent or progressive malignant
glioma. J. Clin. Oncol.
18,3522
-3528.
Gerson, S.L. (2002) Clinical relevance of MGMT in the
treatment of cancer. J. Clin. Oncol.
20,2388
-2399.
Gilbert, M.R., Friedman, H.S., Kuttesch, J.F., Prados, M.D., Olson, J.J., Reaman, G.H., and Zaknoen, S.L. (2002) A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-Oncol. 4, 261-267.[Abstract]
GMT. Glioma Meta-Analysis Trialists (GMT) Group. (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359,1011 -1018.[CrossRef][Web of Science][Medline]
Jaeckle, K.A., Eyre, H.J., Townsend, J.J., Schulman, S., Knudson, H.M., Belanich, M., Yarosh, D.B., Bearman, S.I., Giroux, D.J., and Schold, S.C. (1998) Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. J. Clin. Oncol. 16,3310 -3315.[Abstract]
Levin, V.A., Uhm, J.H., Jaeckle, K.A., Choucair, A., Flynn, P.J.,
Yung, W.K.A., Prados, M.D., Bruner, J.M., Chang, S.M., Kyritsis, A.P.,
Gleason, M.J., and Hess, K.R. (2000) Phase III randomized study
of postradiotherapy chemotherapy with
alpha-difluoromethylornithine-procarbazine,
N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV)
versus PCV for glioblastoma multiforme. Clin. Cancer
Res. 6,3878
-3884.
Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8,1277 -1280.[Abstract]
Medical Research Council Brain Tumor Working Party
(2001) Randomized trial of procarbazine, lomustine, and
vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical
Research Council trial. J. Clin. Oncol.
19,509
-518.
Mitchell, R.B., and Dolan, M.E. (1993) Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol. 32,59 -63.[CrossRef][Web of Science][Medline]
NCI. National Cancer Institute, Cancer Therapy Evaluation Program (1999) Common Toxicity Criteria—Version 2.0. Rockville, Md.: NCI Division of Cancer Treatment and Diagnosis (available at http://ctep.cancer.gov/reporting/ctc.html).
Pegg, A.E. (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 462,83 -100.[CrossRef][Web of Science][Medline]
Plowman, J., Waud, W.R., Koutsoukos, A.D., Rubinstein, L.V., Moore,
T.D., and Grever, M.R. (1994) Preclinical antitumor activity of
temozolomide in mice: Efficacy against human brain tumor xenografts and
synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer
Res. 54,3793
-3799.
Quinn, J.A., Pluda, J., Dolan, M.E., Delaney, S., Kaplan, R., Rich,
J.N., Friedman, A.H., Reardon, D.A., Sampson, J.H., Colvin, O.M., Haglund,
M.M., Pegg, A.E., Moschel, R.C., McLendon, R.E., Provenzale, J.M., Gururangan,
S., Tourt-Uhlig, S., Herndon, J.E., 2nd, Bigner, D.D., and Friedman, H.S.
(2002) Phase II trial of carmustine plus O(6)-benzylguanine for
patients with nitrosourea-resistant recurrent or progressive malignant glioma.
J. Clin. Oncol. 20,2277
-2283.
Quinn, J.A., Reardon, D.A., Friedman, A.H., Rich, J.N., Sampson,
J.H., Provenzale, J.M., McLendon, R.E., Gururangan, S., Bigner, D.D., Herndon,
J.E., 2nd, Avgeropoulos, N., Finlay, J., Tourt-Uhlig, S., Affronti, M.L.,
Evans, B., Stafford-Fox, V., Zaknoen, S., and Friedman, H.S.
(2003) Phase II trial of temozolomide in patients with
progressive low-grade glioma. J. Clin. Oncol.
21,646
-651.
Schilsky, R.L., Dolan, M.E., Bertucci, D., Ewesuedo, R.B.,
Vogelzang, N.J., Mani, S., Wilson, L.R., and Ratain, M.J. (2000)
Phase I clinical and pharmacological study of O6-benzylguanine followed by
carmustine in patients with advanced cancer. Clin. Cancer
Res. 6,3025
-3031.
Schold, S.C., Kuhn, J.G., Chang, S.M., Bosik, M.E., Robins, H.I., Mehta, M.P., Spence, A.M., Fulton, D., Fink, K.L., and Prados, M.D. (2000) A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study. Neuro-oncol. 2,34 -39.[Abstract]
Slancar, M., Wheeler, H., Cook, R., Levi, J., Bell, D., and Beith, J. (1997) Increased pulmonary toxicity with scheduling procarbazine prior to BCNU in patients with high-grade gliomas. Proc. Am. Soc. Clin. Oncol. 16, 409a (abstract).
Tolcher, A.W., Gerson, S.L., Denis, L., Geyer, C., Hammond, L.A., Patnaik, A., Goetz, A.D., Schwartz, G., Edwards, T., Reyderman, L., Statkevich, P., Cutler, D.L., and Rowinsky, E.K. (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer 88,1004 -1011.[CrossRef][Web of Science][Medline]
Wedge, S.R., Porteus, J.K., May, B.L., and Newlands, E.S. (1996) Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: A comparative study in vitro. Br. J. Cancer 73,482 -490.[Web of Science][Medline]
Westerhof, G.R., Down, J.D., Blokland, I., Wood, M., Boudewijn, A., Watson, A.J., McGown, A.T., Ploemacher, R.E., and Margison, G.P. (2001) O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells. Exp. Hematol. 29,633 -638.[CrossRef][Web of Science][Medline]
Yung, W.K.A., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83,588 -593.[CrossRef][Web of Science][Medline]
Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada,
M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M.,
Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A.
(1999) Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
J. Clin. Oncol. 17,2762
-2771.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Herrlinger, J. Rieger, D. Koch, S. Loeser, B. Blaschke, R.-D. Kortmann, J. P. Steinbach, T. Hundsberger, W. Wick, R. Meyermann, et al. Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03 J. Clin. Oncol., September 20, 2006; 24(27): 4412 - 4417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
